JPMorgan Chase & Co. Reiterates “Overweight” Rating for bluebird bio (BLUE)
bluebird bio (NASDAQ:BLUE)‘s stock had its “overweight” rating reiterated by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Wednesday. They currently have a $53.00 price target on the stock, up from their previous price target of $44.00. JPMorgan Chase & Co.’s price objective would suggest a potential upside of 45.32% from the stock’s previous close.
In other bluebird bio news, COO Jeffrey T. Walsh unloaded 6,000 shares of bluebird bio stock on the open market in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $24.23, for a total transaction of $145,380.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of bluebird bio (NASDAQ:BLUE) remained flat at $36.47 during during mid-day trading trading on Wednesday. 132,199 shares of the company’s stock traded hands. bluebird bio has a 1-year low of $17.03 and a 1-year high of $41.75. The stock’s 50-day moving average is $23.17 and its 200-day moving average is $22.64. The company’s market cap is $893.9 million.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.44) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.32) by $0.12. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.23 million. Analysts expect that bluebird bio will post $-1.78 EPS for the current fiscal year.
A number of other firms have also recently commented on BLUE. Analysts at Wedbush raised their price target on shares of bluebird bio to $51.00 in a research note on Monday. Separately, analysts at Piper Jaffray initiated coverage on shares of bluebird bio in a research note on Friday, June 13th. They set an “overweight” rating on the stock. Finally, analysts at Zacks upgraded shares of bluebird bio from an “underperform” rating to a “neutral” rating in a research note on Wednesday, May 14th. They now have a $19.90 price target on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $42.48.
bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.